Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nhwa to Distribute Teva’s Movement Disorder Therapies in China

publication date: Feb 27, 2024

Jiangsu Nhwa Pharma formed a China partnership to distribute a Teva Pharma therapy that treats two neurodegenerative and movement disorders - chorea associated with Huntington’s disease and tardive dyskinesia in adults. Teva’s Austedo is the only vesicular monoamine transporter 2 inhibitor approved by the US FDA for adults with either condition. Austedo, a deuterated drug, replaces hydrogen atoms with deuterium, which is expected to lower metabolism rates and facilitate less frequent dosing. Nhwa’s focus is on providing new therapies for China’s neuro-psychiatric health sector. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital